Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Grabinski, Nicole, Ewald, Florian, Hofmann, Bianca T, Staufer, Katharina, Schumacher, Udo, Nashan, Björn, Jücker, Manfred
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2012
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://ncbi.nlm.nih.gov/pubmed/23167739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-85
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares